The effect of @entity4444 in non- XXXX . Experience with a multi-cross-over model.

@entity4444 @entity1 @entity1066 @entity10189
The symptomatic effect of @entity4444 was examined in 27 @entity1 with non- @entity1066 (NUD) by means of a multi-cross-over model (MCO model) for testing the symptomatic effect of drugs in individual @entity1 . None of the @entity1 showed an @entity1066 at the time, but 20 @entity1 had evidence of previous @entity10189 . The variant of the MCO model used included six treatment periods and three regular interchanges between @entity4444 and placebo. Treatment periods lasted 2 or 4 days. The individual results were evaluated on the basis of the number of times (X score) @entity4444 was associated with less symptoms than the preceding or following placebo. In general, @entity4444 was associated with significantly (p less than 0.02) less symptoms than placebo. The X-score distribution was therefore skew in favour of high scores. Five @entity1 showed the maximal X score of 5. The chance of getting an X score of 5 when @entity4444 is not better than placebo is about 9%. Accordingly, the risk of being wrong when defining these five @entity1 as @entity4444 responders is 9%. The present study confirms that the MCO model may identify individual @entity4444 responders among @entity1 with NUD.
